CONTENTS

Chapter 4. CDER and the IND Review Process 63
The FDA's Center for Drug Evaluation and Research 63
CDER's Review Divisions 66
Division of Oncologic Drug Products 76
Division of Biological Oncology Products 68
Division of Medical Imaging and Hematology Products 68
Division of Cardiovascular and Renal Products 69
Division of Neurology Products 69
Division of Psychiatry Products 69
Division of Metabolism and Endocrinology Products 69
Division of Pulmonary and Allergy Products 70
Division of Anesthesia, Analgesia, and Rheumatology Products 70
Division of Reproductive and Urologic Drug Products 70
Division of Gastroenterology Products 70
Division of Dermatology and Dental Products 70
Division of Anti-Infective and Ophthalmology Products 71
Division of Antiviral Drug Products 71
Division of Special Pathogen and Transplant Products 71
Office of Nonprescription Products 72
Inside the FDA's Drug Review Divisions 72
The IND Review Process 74
Initial Processing of the IND 76
The IND within the Review Division 77
Pharmacology Review 77
Chemistry Review 78
Clinical Review 78
Microbiology Review 78
The 30-Day Review Clock 79
The Clinical Hold 80
IND Status 83

Chapter 5. The Clinical Development of New Drugs 85
The FDA's Role in Clinical Trials 92
The Structure of Clinical Trials 94
Phase 1 Clinical Trials 97
PK/PD and Phase 1 Trials 99
Sponsor Information/Data Submissions During Clinical Trials 100
Phase 2 Clinical Trials 101
End-of-Phase 2 Meetings and Other FDA-Sponsor Communication During Clinical Trials 103
Phase 3 Clinical Trials 106
Pivotal Clinical Studies 107
Standards for Pivotal Trials 109
Clinical Trials and the Safety Data Base 112
Completing a Drug's Clinical Study 114
Phase 4 Clinical Studies 117

Chapter 6. Good Clinical Practices (GCP) 119
Recent Developments in GCP 120
Responsibilities of the Sponsor 122
Selecting Investigators and Monitors 122

Informing Investigators 124
Review of Ongoing Investigations 125
Recordkeeping and Record Retention 126
Disposition of Unused Drug Supplies 126
Sponsors and Data Safety Monitoring Boards 126
Responsibilities of Investigators 127
Control of the Product 128
Recordkeeping and Record Retention 128
Investigator Reports 128
Assurance of IRB Review 128
Handling of Controlled Substances 128
The Institutional Review Board (IRB) 129
Informed Consent 130

Chapter 7. The New Drug Application (NDA) 133
The History of the NDA 135
NDA Content and Format Requirements 137
The Common Technical Document/Electronic Common Technical Document 137
The Fundamentals of NDA Submissions 145
The Archival, Review, and Field Copies of the NDA 146
Application Form 150
The Index 150
Labeling 150
The "Content of Labeling" Section 150
The NDA Summary 151
Chemistry Section 152
Nonclinical Pharmacology and Toxicology Section 160
Human Pharmacokinetics and Bioavailability Section 161
Microbiology Section 162
Clinical Data Section 163
Safety Update Report Section 166
Statistical Section 167
Pediatric Assessment 167
Case Report Tabulations Section 168
Case Report Forms Section 169
Patent Information 170
Patent Certification 170
Establishment Description 170
Debarment Certification 170
Field Copy Certification 170
User Fee Cover Sheet (Form FDA 3397) 170
Financial Information Section 171
Other Information 172
Other Possible Elements of the NDA: RiskMAPs, REMS and Pharmacogenomic Data 172
The NDA and Risk Minimization Action Plans 173
REMS 174
Pharmacogenomic Data and the NDA 175
Complete versus Partial NDA Submissions 176
The GRMPs and the Wisdom of Complete NDA Filings 176
PDUFA, the Rolling NDA, and the Reviewable Unit Pilot 178
Pre-NDA Meetings 179

Assembling and Submitting the NDA 181
Amending the NDA 181

Chapter 8. The NDA Review Process 183
The NDA Review Process in the PDUFA Era 183
A Profile of the NDA Review Process 187
Initial Processing of the NDA 188
Processing Within the Drug Review Division 188
The FDA's Refuse-to-File Authorities 190
PDUFA and Early Notification of NDA Issues 194
The Preapproval Inspection 195
The Primary Review Process 197
Clinical Review 197
Pharmacology/Toxicology Reviewer 198
Chemistry Reviewer 198
Statistical Reviewer 198
Biopharmaceutics Reviewer 198
Microbiology Reviewer 198
Bioresearch Monitoring Reviewer 199
Mid-Review CDER/Sponsor Communications 199
Emerging Elements of the NDA Review Process: RiskMAPs, REMS, and Pharmacogenomic Data 201
Reaching an Institutional Decision on the NDA 203
The Formal Action on an NDA 205
FDA Action Letters 207
Approval Letter 207
Approvable Letter 209
Not-Approvable Letter 210
Applicant Responses to Approvable or Not-Approvable Letters 211
Final Printed Labeling 212
Draft Package Labeling 213
The FDA's Review of Draft Labeling 215
Sponsor Rights During the NDA Review Process 216
The Right to a Timely Review 216
The Right to Meetings 218
The Right to Protest and Appeal FDA Actions/Decisions 220
The Right to Confidentiality 222
Proposed Changes to NDA Confidentiality Standards 224

Chapter 9. The FDA's Priority Review Policy 225
Therapeutic Rating 226
Assigning the Therapeutic Rating 227
Chemical Classification 228
CDER's Prioritization Policy at Work 230
The Impact of CDER's Priority Review Policy 230
Patterns in Priority/Standard Designations for New Drugs 231

Chapter 10. Advisory Committees and the Drug Approval Process 233
A Look at Committee Membership 236
Conflict of Interest Standards for Committee Members 237
When CDER Uses Advisory Committees 240

How Advisory Committees Function 241
Committee Meeting Scheduling and Practices 242
How Influential Are CDER's Advisory Committees? 244
What Sponsors Should Know About Advisory Committees 245

Chapter 11. Beyond Approval: Postmarketing Drug Manufacturer Regulatory Responsibilities . . . 247
General Reporting Requirements 248
Field Alert Reports 248
Annual Reports 248
Other Reports 251
Adverse Drug Experience Reporting Requirements 252
Key Definitions Relevant to Adverse Drug Experience Reporting 254
Adverse Drug Experience Reporting Requirements 255
Pending Revisions to the FDA's Postmarketing AE Reporting Requirements 259
Current Good Manufacturing Practice (cGMP) 261
The Pharmaceutical cGMPs for the 21st Century Initiative 262
The FDA's cGMP Standards 264
The Enforcement of cGMP 267
Phase 4 Commitments 268
FDAAA and New FDA Powers to Require Postmarketing Studies/Trials 268
Trends in Postmarketing Commitments for New Drugs 272
Post-Approval Risk Management 272

Chapter 12. The Supplemental NDA and Postapproval Changes to Marketed Drugs 275
Recent History of Regulatory Reform and sNDAs 275
When to Submit Supplemental versus Original NDAs 276
Supplemental NDA Submission Requirements 277
Postmarketing Manufacturing Changes 278
FDAMA and Postmarketing Manufacturing Changes 278
SUPAC and sNDAs for Manufacturing Changes 279
CDER's PQAS and Manufacturing Supplements 280
Expedited Review for NDA Chemistry Supplements 281
"Bundled" CMC Supplements 281
Labeling Changes 282
Pursuing New Indications for Approved Drugs 283
Submission and Approval Trends for Efficacy Supplements 284

Chapter 13. The FDA's Orphan Drug Development Program 285
The FDA and Orphan Drugs: A Brief History 286
The Significance of Orphan Drug Designation 286
Obtaining Orphan Drug Designation 287
A Look at Orphan Drug Incentives 289
Marketing Exclusivity 290
Tax Credits 292
Protocol Assistance 292
FDA Grants and Contracts 293
The FDA Approval Process: Advantages for Orphan Drugs? 293

Chapter 14. CDER's Bioresearch Monitoring Program 295
A Brief History of the Bioresearch Monitoring Program 297
The Clinical Investigator Compliance Program 298

Data Audit Inspection Program 299
For Cause Inspection Program 300
Bioequivalency/Bioavailability Inspection Program 301
Post-Inspectional FDA Actions 303
The Sponsor/Monitor Compliance Program 303
The Inspection of Drug Sponsors 304

Chapter 15. Accelerated Drug Approval/Expanded Access Programs 307
Recent Developments in Expanded Access/Accelerated Development Programs 309
The Treatment IND 310
Treatment Use for Immediately Life-Threatening Conditions 311
Treatment Use for Serious Conditions 312
Obtaining FDA Permission for Treatment Use 312
The Sale of Investigational Drugs 313
The FDA's Accelerated Drug Development Program (Subpart E) 317
Eligibility for Accelerated Development 317
The Cornerstone of Accelerated Development: Early FDA-Sponsor Consultation 318
Restructuring Clinical Trials 318
Accelerated Drug Approval Program (Subpart H) 320
Eligibility for Accelerated Approval 324
The Parallel Track Program 325
The Oncology Initiative 325
Fast Track Initiative 327
Qualifying for Fast Track Status 328
Seeking a Fast Track Designation 330
Fast Track and the Rolling NDA 331
Industry Success Rates in Obtaining Fast Track Status 332
FDA Proposal to Overhaul Experimental Drug Access Programs 333

Chapter 16. The Pediatric Studies Initiative 339
Historical Development 339
The Carrot: FDAMA Pediatric Exclusivity as Reauthorized Under the Best Pharmaceuticals for Children Act (BPCA) 340
Off-Patent Incentive Program 343
Modifications to the Pediatric Exclusivity Program Under the 2007 Reauthorization of BPCA 344
The Stick: The FDA's 1998 Rule as Codified Under the Pediatric Research Equity Act (PREA) 345
Modifications to Required Pediatric Assessment Under the 2007 Reauthorization of PREA 348
Incorporating Pediatric Studies into Drug Development Planning 350
Planning Considerations I: What Types of Studies Will Be Needed? 350
Planning Considerations II: How Often Will New Formulations be Needed? 354
Planning Considerations III: When Should Pediatric Studies Be Initiated? 356
Planning Considerations IV: What Information Resources Are Available? 357
The Present 358
The Future 360